The deal is for 3 years, and makes Thorne its partner for products containing NR in nutritional supplements, exclusively for the direct to healthcare-practitioner channel in the US and Canada. The deal is stated to be worth at least $3.5 million. ChromaDex will get royalty payments for use of the ingredient by Thorne in the products. The structure of the deal, the initial payments etc. have not been declared yet. Those details may come out soon, and will help understand the exact impact of the deal on the short term and long term future of the company. The two companies will also have a collaboration regarding the human clinical research on NR. Thorne intends to launch many first-to-market products containing NR in this particular sector. As per the CEO of CDXC, the company has received numerous queries, and other companies are also interested in NR. The deal indicates that the molecule has a lot of potential, and may help the company strengthen its financial position in long term. The company had recently entered into an agreement with Scripps Research Institute for more research on NR. High Performance Nutrition had recently launched a product containing NR for neuroprotection in contact sports. It will be interesting to see how the products perform in the marketplace. That will squarely depend on the efficacy of the products in the indications for which it is being promoted. It is more than likely that the product succeeds in delivering the intended benefits in one or more indications. Success in specific indications like weight loss, increased muscle endurance, protection of nerve cells from injury etc., can have significant effect on the financials of the company. It will also increase awareness about the molecule and encourage more research. That is likely to have cascading positive effects.